Literature DB >> 31198550

False-positive hepatitis B test results after intravenous immunoglobulin therapy.

Anne Wil J den Hoed-Krijnen1, Peter J H Smak Gregoor1.   

Abstract

Entities:  

Year:  2019        PMID: 31198550      PMCID: PMC6544086          DOI: 10.1093/ckj/sfz035

Source DB:  PubMed          Journal:  Clin Kidney J        ISSN: 2048-8505


× No keyword cloud information.
A 75-year-old male patient returned to our centre for peritoneal dialysis after transplantectomy due to renal transplant rejection. Routine viral screening prior to resuming dialysis indicated anti-Hepatitis B (anti-HB titre of 363 IU/L [anti-Hepatitis Bcore (anti-HBc) and Hepatitis Be antigen (HBeAg) both negative], which suggested that the patient received hepatitis B vaccination. However, both patient and the referring centre denied vaccination. The patient’s anti-HB titres decreased over time (Table 1).
Table 1.

Course of anti-HB titres and relevant events

DateEventAnti-HB titres (IU/L)
June 2017Dialysis<3, 10
October 2018IVIG therapy
October 2018Transplantectomy
5 November 2018Blood test363
29 November 2018Blood test195
13 December 2018Blood test101
Course of anti-HB titres and relevant events During anti-rejection therapy, the patient received intravenous immunoglobulin (IVIG) therapy. The possibility of passive transfer of hepatitis B antibodies after IVIG administration resulting in false-positive hepatitis B serology and partial passive immunization following IVIG has been described [1-4]. Attention to the possibility of this passive immunization is important, as it can lead to misinterpretation of test results with implications for further treatment. This phenomenon may be more prevalent with the increased use of IVIG in transplant rejection nowadays.

CONFLICT OF INTEREST STATEMENT

None declared.
  4 in total

1.  False-positive hepatitis B serology following IVIG therapy: forgotten but not gone!!

Authors:  Emma Benton; Kamran Iqbal; Paul Wade; Terry Wong; Emma Aarons; Richard Groves
Journal:  J Am Acad Dermatol       Date:  2012-03       Impact factor: 11.527

2.  Misleading hepatitis B test results due to intravenous immunoglobulin administration: implications for a clinical trial of rituximab in immune thrombocytopenia.

Authors:  Donald M Arnold; Mark A Crowther; Ralph M Meyer; Julie Carruthers; Julie Ditomasso; Nancy M Heddle; Anne McLeod; John G Kelton
Journal:  Transfusion       Date:  2010-12       Impact factor: 3.157

3.  Antibodies against Hepatitis A and Hepatitis B Virus in Intravenous Immunoglobulin Products.

Authors:  Soyoung Lee; Han Wool Kim; Kyung Hyo Kim
Journal:  J Korean Med Sci       Date:  2016-12       Impact factor: 2.153

4.  Case report: passive transfer of hepatitis B antibodies from intravenous immunoglobulin.

Authors:  Simon Parker; Eliza Gil; Patricia Hewitt; Katherine Ward; Yasmin Reyal; Sasha Wilson; Jessica Manson
Journal:  BMC Infect Dis       Date:  2014-02-22       Impact factor: 3.090

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.